RaySearch Deepens Collaboration with P-Cure

RaySearch Laboratories AB (publ) is pleased to announce its expanded collaboration with P-Cure, aiming at enhancing the workflow efficiency of P-Cure’s proton therapy system through integration with RaySearch’s systems RayStation®* and RayCare®*.

The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment. The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA. It is used clinically by the Hadassah Medical Center in Jerusalem – the only proton facility in the Middle East – to treat CNS, head and neck, thoracic and pancreatic malignancies.

The partnership is an organic continuation of the existing relationship between the companies that has already resulted in integration of RayStation in a study conducted at the P-Cure clinical development center, operated clinically by Hadassah Medical Center.

The partnership will enable users of the P-Cure proton therapy system to also utilize the automation and workflow support provided by RayCare, as well as the features for adaptive radiation therapy in the RaySearch systems.

Dr. Michael Marash, CEO of P-Cure, says: “Our partnership with RaySearch, the world leader in treatment planning, will play an important role in our pioneering efforts to bring the benefits of proton therapy to help a far larger world-wide patient body. I am happy that we have now taken our partnership to the next level and I believe our technologies have great potential together.”

Johan Löf, founder and CEO, RaySearch, says: “We are proud to work with a company that is ushering in a new era of proton therapy. P-Cure is a pioneer in the development of upright radiation therapy, and the ability to provide a proton system in a regular linac room has great potential to expand proton therapy.”

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.